myelopathy due to acquired copper deficiency in humans, 2 it is likely that the condition remains under-recognized. In the North of England alone, five cases of copper deficiency myelopathy (CDM) have been diagnosed since the local index case raised awareness in late 2006. 3 The most common cause of CDM is previous upper gastrointestinal surgery, which was implicated in 47% of reported cases (review in preparation by authors). In the past, such surgery was typically performed for peptic ulcer disease, but with the advent of proton pump inhibitors and increasing levels of obesity, bariatric surgery is likely to take over as the leading risk factor. 4 The second most common cause of CDM is hyperzincaemia. In addition to the causes listed by the authors, denture cream can be a source of spurious zinc excess which has recently been associated with four cases of CDM and is easily missed by the unaware. 5 Although primary dietary copper deficiency could potentially give rise to CDM, such an association has not been reported to date.
Bertfield et al. (Ann Clin Biochem 2008;45:434 -435) address the pathogenesis of the haematological manifestations, but not that of the neurological syndrome. It has been suggested that copper deficiency causes myelopathy through dysfunction of cytochrome oxidase, which is known to be copperdependent. 6 However, this enzyme is not cobalamindependent, so this hypothesis does not readily explain the marked phenotypic parallels between CDM and subacute combined degeneration of the cord due to cobalamin deficiency (SCD). We have recently proposed that CDM and SCD share dysfunction of the methylation cycle as their final common pathway, which would explain their clinical and radiological similarity. 7 This is the first case in which copper supplementation was given intramuscularly. A parenteral route was chosen because the patient 'would be unable to absorb oral supplements'. Although the absorptive surface for copper is reduced, oral supplementation has been effective in many similar cases so such an approach may not be necessary.
Finally, Bertfield et al. assert that 'treatment with copper may prevent further neurological deterioration'. This is an understatement, since the neurological deficit of all reported cases did stabilize or improve on adequate copper replacement. Timely recognition and treatment are crucial in preventing potentially irreversible neurological disability.
Revised national guidelines for analysis of CSF for bilirubin in suspected SAH
We are pleased to see the evolution of the UK guidelines in this area (Ann Clin Biochem 2008;45:238-244), although contest the view that analysis of bilirubin in CSF using diazo methods has not been adequately validated in this context and should not be used. 1 We developed such an approach to diagnosis, 2,3 now used routinely in our laboratory to identify approximately 90% of samples that do not need to be submitted to spectrophotometry. Our approach employs the measurement of CSF bilirubin on an automated instrument, using the Jendrassik and Gró f method, calibrated to measure lower concentrations. 2 We found that at a CSF bilirubin cut-off of 359 nmol/L, based on our upper reference interval in CSF, there was 100% negative predictive value 2 for a net bilirubin absorbance greater than 0.007, i.e. positive initial scan. In a follow-up study, 3 the validity of this cut-off was confirmed, with no evidence from clinical records to suggest that any case of SAH had been missed. The accompanying editorial, 4 acknowledged that it could thus act as an initial screening method to eliminate those samples that would subsequently prove to be negative spectrophotometrically, thereby allowing the majority of samples to be screened out by a procedure potentially available on a 24-hour basis. An added advantage is that small volumes of sample, around 100 mL (compared with 0.5 mL needed for disposable cuvettes for absorbance scans) are sufficient for the CSF bilirubin determination. 3 Preliminary data suggest some negative interference of haemoglobin on CSF bilirubin, which requires further study and quantitation, although it also affects NBA derived by spectrophotometry. For operational purposes, CSF samples are also submitted to spectrophotometry if our analyser haemolytic index is greater than 2.0 mg/dL.
We believe that this methodology should be easily transferable to similar analytical platforms, although it is imperative that each laboratory should meticulously validate its own analytical performance. It offers a robust test and may be particularly useful in peripheral laboratories as a screen to identify those samples that need to be confirmed by spectrophotometry. 3 
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